Trial Profile

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary)
Indications Multiple sclerosis
Focus Biomarker; Therapeutic Use
Acronyms IMPACT MS

Most Recent Events

19 Sep 2023 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
19 Sep 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
19 Sep 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com